Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Item
http://www.wikidata.org/entity/Q30235198
Icariin Attenuates Synaptic and Cognitive Deficits in an Aβ1-42-Induced Rat Model of Alzheimer's Disease.FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.Progress in brain barriers and brain fluid research in 2017.CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions.Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease.CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.Revolution of Alzheimer Precision Neurology Passageway of Systems Biology and Neurophysiology.Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
P2860

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Item
http://www.wikidata.org/entity/Q30235198
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Clinical validity of cerebrosp ...... 5-phase development framework.
@ast
Clinical validity of cerebrosp ...... 5-phase development framework.
@en
type
label
Clinical validity of cerebrosp ...... 5-phase development framework.
@ast
Clinical validity of cerebrosp ...... 5-phase development framework.
@en
prefLabel
Clinical validity of cerebrosp ...... 5-phase development framework.
@ast
Clinical validity of cerebrosp ...... 5-phase development framework.
@en
P1433
P1476
P2093
P304
P31
P356
P478
P50
P577
P698
P921
P356
P1433
P1476
Clinical validity of cerebrosp ...... 5-phase development framework.
@en
P2093
Geneva Task Force for the Roadmap of Alzheimer's Biomarkers
P304
P31
P356
10.1016/J.NEUROBIOLAGING.2016.02.034
P478
P50
P577
P698
P921